Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.1052W HIGH $8.33
Volume
1.07 M
Value Traded
14.85 M
Short % Float
13.74%
+16.76%Week
-2.65%1 Month
-31.29%3 Month
+73.39%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
456.76 M
EPS (TTM)
-4.47
P/E Ratio
-
Ent. Value
1.31 B
Total Shares
113.11 M
Float Shares
102.41 M
Insiders
9.42%
Institutions
89.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
EVH Catalyst Timeline
Dated clinical, regulatory and corporate events for Evolent Health, Inc Class A Common Stock
Past FDA Catalysts and PDUFA Decisions
How EVH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every EVH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| McCarthy Daniel JosephOfficer (PRESIDENT) | Sell | -65,892 655,133 held | $5.00 | 08/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EVH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.1 % (-80 %) | 4.90 M | 579.05 K | -83.81% ( -3.00 M) |
EVH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EVH ranks across every disease it competes in
Competitive Position is a premium feature
See how EVH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEVH News
-EVH
Oct 9, 2026▲ +2%today
Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Evolent Health, Inc. will announce its third quarter 2026 financial results on November 5, 2026, before the market opens. A conference call will follow at 8:30 a.m. ET, where analysts can ask questions. The call will be available for playback on the company's investor relations website for 90 days.
Read more →-EVH
Aug 6, 2026▲ +16.6%on this news· ran to +33% by day 3
Evolent Announces Second Quarter 2026 Results
Evolent Health, Inc. announced its financial results for Q2 2026, showcasing a revenue of $652.5 million, a significant increase from the previous year. The company anticipates over 25% revenue growth for 2027, driven by strong demand for its oncology solutions. Despite reporting a net loss, Evolent's adjusted EBITDA outlook remains positive, reflecting confidence in its operational model and partnerships. The company is also addressing industry challenges while focusing on improving financial flexibility.
Read more →-EVH
Jul 8, 2026Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Evolent Health, Inc. has announced that it will release its second quarter 2026 financial results on August 6, 2026, before the market opens. A conference call will follow at 8 a.m. ET, where shareholders and analysts can participate. The company emphasizes its commitment to improving healthcare outcomes for complex conditions.
Read more →-EVH
May 7, 2026▲ +11.5%on this news
Evolent Announces First Quarter 2026 Results
Evolent Health, Inc. announced its financial results for the first quarter of 2026, revealing a revenue increase to $496.2 million. The company significantly narrowed its net loss compared to the previous year. CEO Seth Blackley expressed satisfaction with the company’s progression, notably in oncology launches and new revenue agreements expected to yield substantial future revenues. However, a decrease in adjusted EBITDA margin indicates ongoing financial challenges.
Read more →-EVH
Feb 24, 2026▼ -7.6%on this news
Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
Evolent Health, Inc. reported its financial results for Q4 and the full year of 2025, highlighting a revenue of $468,719 for the quarter and $1,876,229 for the year. Despite achieving its earnings targets and strong customer retention, the company faced a substantial net loss of $429,131 in Q4. Evolent expects a robust revenue growth of 30% in 2026, underpinned by the anticipated addition of $900 million in new Performance Suite revenue, although challenges from declining customer memberships are anticipated in the first half of 2026. Overall, the company remains optimistic about market opportunities in its specialty model for healthcare delivery.
Read more →-EVH
Nov 6, 2025▼ -5.5%on this news· ran to -22% by day 1
Evolent Announces Third Quarter 2025 Results Q3 2025 financial results ahead of expectations.
Evolent Health, Inc. announced its financial results for Q3 2025, showcasing revenue ahead of expectations. The company secured over $500 million in new annualized revenue from new contracts for 2026. Leadership changes were made to bolster growth, including the appointment of a new Chief Financial Officer. Despite positive contract growth and a solid product offering, the company still recorded a net loss.
Read more →-EVH
Sep 23, 2025Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners
Evolent Health, Inc. has announced the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group for up to $113 million. The transaction is aimed at focusing Evolent's operations on its core specialty business, while also improving cash flow by over $7 million annually following debt repayment. Evolent has reiterated its revenue and EBITDA outlook for Q3 and full year 2025, indicating stability in financial expectations despite the asset sale.
Read more →-EVH
Aug 19, 2025Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Evolent Health, Inc. announced the pricing of $145 million in convertible senior notes due 2031, aimed at repurchasing existing notes and Class A common stock. The oversubscribed offering, initially set at $140 million, has increased in size, indicating strong investor interest. The chief financial officer highlighted that the transaction will help reduce annual interest expenses and manage shareholder dilution. The net proceeds are projected to facilitate repurchase activities, enhancing the company's financial position.
Read more →-EVH
Aug 18, 2025Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Evolent Health, Inc. has announced a proposed offering of $140 million in convertible senior notes due in 2031. The proceeds from the offering will be primarily used to repurchase existing convertible senior notes and Class A common stock. The initiative aims to enhance the company's financial position, although the successful execution of the offering is contingent on market conditions. Additionally, the share repurchase may lead to shareholder dilution concerns.
Read more →-EVH
Aug 7, 2025Evolent Announces Second Quarter 2025 Results
Evolent Health, Inc. reported its financial results for the second quarter of 2025, showing a significant increase in net loss compared to the previous year while exceeding EBITDA targets and raising its profitability outlook. The company is experiencing rapid growth in its business pipeline and aims to innovate further in the healthcare space through AI solutions. However, revenue has decreased compared to the same period last year, highlighting ongoing challenges in the health industry. Evolent anticipates continued strong customer retention and projects increased revenue for the full year.
Read more →-EVH
Jun 20, 2025▲ +6.9%on this news· ran to +24% by day 3
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Evolent Health, Inc. has reiterated its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and full year guidance of $135M-$165M, citing positive oncology cost trends. The company has secured a Commitment Letter for additional non-dilutive capital which will aid in managing its capital needs related to a forecasted increase in revenue bookings for 2026. Evolent's leadership expresses confidence in meeting financial expectations, bolstered by favorable operational indicators.
Read more →-EVH
May 8, 2025Evolent Announces First Quarter 2025 Results
Evolent Health, Inc. announced its financial results for the first quarter of 2025, showing a net loss of $72.3 million, which represents a decline compared to $25.2 million reported in the same period last year. Despite this, the company achieved revenue of $483.6 million and noted a strong selling environment, with five new revenue agreements. Evolent reiterated its revenue outlook for the full year 2025, expecting revenue between $2.06 billion to $2.11 billion, while focusing on enhancing specialty care solutions.
Read more →-EVH
Apr 22, 2025Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
Evolent Health has nominated Shawn Guertin for election to its Board of Directors at the upcoming annual meeting. Guertin, who has extensive experience in the health care industry, most recently served as CFO of CVS Health. His nomination aligns with Evolent's ongoing efforts to refresh its board and enhance governance practices. If elected, he would succeed Diane Holder, who is stepping down after 14 years.
Read more →-EVH
Feb 20, 2025Evolent Announces Fourth Quarter and Full Year 2024 Results
Evolent Health, Inc. reported financial results for Q4 and full year 2024, achieving revenues of $646.5 million for the quarter and $2.55 billion for the year, reflecting significant growth compared to 2023. Despite this achievement, the company posted a net loss of $30.6 million for the quarter and $93.5 million for the year, with net loss margins of (4.7)% and (3.7)%, respectively. Evolent highlighted a successful contract retention strategy, achieving 100% retention among top customers. Looking ahead, the company anticipates an improvement in its financial outlook through contract adjustments and growth in complex care solutions.
Read more →-EVH
Feb 4, 2025Evolent Health Announces Changes to Board of Directors Richard "Rick" Jelinek to Be Named Chair of the Board at 2025 Annual Meeting
Evolent Health has announced significant changes to its Board of Directors, appointing Rick Jelinek as Chair, effective at the 2025 Annual Meeting. Brendan Springstubb has joined the board as an independent director, bringing extensive experience in healthcare investments. This move is part of Evolent’s ongoing efforts to refresh its board and strengthen corporate governance, with plans for further director appointments ahead of the upcoming annual meeting.
Read more →-EVH
Nov 7, 2024Evolent Announces Third Quarter 2024 Results Revenue of $621.4 million, an increase of $110.4 million or 21.6% , from the three months ended
Evolent Health, Inc. reported third-quarter 2024 revenue of $621.4 million, up by 21.6% from the previous year. However, the company faced a net loss of $31.2 million and a decrease in Adjusted EBITDA. Despite challenges, Evolent announced six new record contract agreements and expresses optimism about future growth in specialty care solutions. The financial outlook for the fourth quarter and full year has been adjusted to reflect anticipated revenue and EBITDA targets.
Read more →-EVH
Aug 8, 2024Evolent Announces Second Quarter 2024 Results Revenue of $647.1 million, an increase of $178.0 million or 37.9% , from the three months ended
Evolent Health, Inc. reported strong financial results for Q2 2024, with revenue of $647.1 million representing a 37.9% increase from the previous year. Despite a net loss of $6.4 million, the company highlighted consistent profitability and positive cash flow. The firm also narrows its revenue outlook for FY 2024, projecting approximately $2.56 billion to $2.60 billion in revenue. CEO Seth Blackley expressed confidence in meeting adjusted EBITDA guidance and underscored successful new revenue agreements.
Read more →-EVH
Jun 4, 2024Document Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's
Evolent Health, Inc. has signed an agreement to acquire artificial intelligence-based utilization management products and the team from Machinify. This acquisition is intended to enhance the efficiency and clinical quality of Evolent's specialty management platform through AI-enabled automation. The deal includes a proven software platform, Machinify Auth, which is expected to significantly reduce clinician workload and streamline data management. The acquisition is set to close in the third quarter of 2024 and is anticipated to bring added value to Evolent's client base.
Read more →-EVH
May 9, 2024Evolent Announces First Quarter 2024 Results Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended
Evolent Health, Inc. reported strong financial results for the first quarter of 2024, with revenue of $639.7 million, a 49.6% increase from the same period last year. Despite facing a net loss of $25.2 million, the company raised its revenue outlook for the full year and reiterated its Adjusted EBITDA guidance. The company also highlighted successful integration efforts post-acquisition and advancements in patient navigation and artificial intelligence through strategic partnerships. However, challenges in the health plans sector were acknowledged, impacting their overall financial metrics.
Read more →About Evolent Health, Inc Class A Common Stock
Headquarters1812 NORTH MOORE ST, SUITE 1705, ARLINGTON, VA, 22209
BIOPHARMAWATCH ELITE PLUS
Trade the next EVH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime